Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

Angela Dispenzieri; Francis Buadi; Shaji K. Kumar; Craig B. Reeder; Tamur Sher; Martha Q. Lacy; Robert A. Kyle; Joseph R. Mikhael; Vivek Roy; Nelson Leung; Martha Grogan; Prashant Kapoor; John A. Lust; David Dingli; Ronald S. Go; Yi Lisa Hwa; Suzanne R. Hayman; Rafael Fonseca; Sikander Ailawadhi; P. Leif Bergsagel; Ascher Chanan-Khan; S. Vincent Rajkumar; Stephen J. Russell; Keith Stewart; Steven R. Zeldenrust; Morie A. Gertz

doi:10.1016/j.mayocp.2015.06.009

Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

Angela Dispenzieri, Francis Buadi, Shaji K. Kumar, Craig B. Reeder, Tamur Sher, Martha Q. Lacy, Robert A. Kyle, Joseph R. Mikhael, Vivek Roy, Nelson Leung, Martha Grogan, Prashant Kapoor, John A. Lust, David Dingli, Ronald S. Go, Yi Lisa Hwa, Suzanne R. Hayman, Rafael Fonseca, Sikander Ailawadhi, P. Leif BergsagelAscher Chanan-Khan, S. Vincent Rajkumar, Stephen J. Russell, Keith Stewart, Steven R. Zeldenrust, Morie A. Gertz

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.

Original language	English (US)
Pages (from-to)	1054-1081
Number of pages	28
Journal	Mayo Clinic proceedings
Volume	90
Issue number	8
DOIs	https://doi.org/10.1016/j.mayocp.2015.06.009
State	Published - Aug 1 2015

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.mayocp.2015.06.009

Cite this

Dispenzieri, A., Buadi, F., Kumar, S. K., Reeder, C. B., Sher, T., Lacy, M. Q., Kyle, R. A., Mikhael, J. R., Roy, V., Leung, N., Grogan, M., Kapoor, P., Lust, J. A., Dingli, D., Go, R. S., Hwa, Y. L., Hayman, S. R., Fonseca, R., Ailawadhi, S., ... Gertz, M. A. (2015). Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clinic proceedings, 90(8), 1054-1081. https://doi.org/10.1016/j.mayocp.2015.06.009

Dispenzieri, A, Buadi, F, Kumar, SK, Reeder, CB, Sher, T , Lacy, MQ, Kyle, RA, Mikhael, JR, Roy, V, Leung, N, Grogan, M , Kapoor, P, Lust, JA, Dingli, D, Go, RS, Hwa, YL, Hayman, SR, Fonseca, R , Ailawadhi, S , Bergsagel, PL , Chanan-Khan, A , Rajkumar, SV , Russell, SJ, Stewart, K, Zeldenrust, SR & Gertz, MA 2015, 'Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement', Mayo Clinic proceedings, vol. 90, no. 8, pp. 1054-1081. https://doi.org/10.1016/j.mayocp.2015.06.009

@article{2133504b4d99494a8a059f9586308002,

title = "Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement",

abstract = "Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.",

author = "Angela Dispenzieri and Francis Buadi and Kumar, {Shaji K.} and Reeder, {Craig B.} and Tamur Sher and Lacy, {Martha Q.} and Kyle, {Robert A.} and Mikhael, {Joseph R.} and Vivek Roy and Nelson Leung and Martha Grogan and Prashant Kapoor and Lust, {John A.} and David Dingli and Go, {Ronald S.} and Hwa, {Yi Lisa} and Hayman, {Suzanne R.} and Rafael Fonseca and Sikander Ailawadhi and Bergsagel, {P. Leif} and Ascher Chanan-Khan and Rajkumar, {S. Vincent} and Russell, {Stephen J.} and Keith Stewart and Zeldenrust, {Steven R.} and Gertz, {Morie A.}",

note = "Publisher Copyright: {\textcopyright} 2015 Mayo Foundation for Medical Education and Research.",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/j.mayocp.2015.06.009",

language = "English (US)",

volume = "90",

pages = "1054--1081",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "8",

}

TY - JOUR

T1 - Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

AU - Dispenzieri, Angela

AU - Buadi, Francis

AU - Kumar, Shaji K.

AU - Reeder, Craig B.

AU - Sher, Tamur

AU - Lacy, Martha Q.

AU - Kyle, Robert A.

AU - Mikhael, Joseph R.

AU - Roy, Vivek

AU - Leung, Nelson

AU - Grogan, Martha

AU - Kapoor, Prashant

AU - Lust, John A.

AU - Dingli, David

AU - Go, Ronald S.

AU - Hwa, Yi Lisa

AU - Hayman, Suzanne R.

AU - Fonseca, Rafael

AU - Ailawadhi, Sikander

AU - Bergsagel, P. Leif

AU - Chanan-Khan, Ascher

AU - Rajkumar, S. Vincent

AU - Russell, Stephen J.

AU - Stewart, Keith

AU - Zeldenrust, Steven R.

AU - Gertz, Morie A.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.

AB - Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.

UR - http://www.scopus.com/inward/record.url?scp=84938573654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938573654&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2015.06.009

DO - 10.1016/j.mayocp.2015.06.009

M3 - Article

C2 - 26250727

AN - SCOPUS:84938573654

SN - 0025-6196

VL - 90

SP - 1054

EP - 1081

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 8

ER -

Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this